Citius pharmaceuticals receives non-compliance notice from nasdaq

On october 30, 2019, citius pharmaceuticals, inc., or the company, received written notice from the nasdaq stock market, or nasdaq, indicating that, because the closing bid price for the company’s common stock has fallen below $1.00 per share for 30 consecutive business days, the company no longer complies with the $1.00 minimum bid price requirement for continued listing on the nasdaq capital market under rule 5550(a)(2) of the nasdaq listing rules. the notification of noncompliance has no immediate effect on the listing or trading of the company’s common stock or its warrants to purchase common stock on the nasdaq capital market under the symbol “ctxr” and “ctxrw,” respectively. pursuant to nasdaq marketplace rule 5810(c)(3)(a), the company has been provided an initial compliance period of 180 calendar days, or until april 27, 2020, to regain compliance with the minimum bid price requirement. to regain compliance, the closing bid price of the company’s common stock must meet or exceed $1.00 per share for a minimum of 10 consecutive business days prior to april 27, 2020. in that event, nasdaq will provide the company with a written confirmation of compliance and the matter will be closed. the company intends to consider all available alternatives to regain compliance with rule 5550(a)(2) to allow for continued listing of the common stock on the nasdaq capital market. if the company does not regain compliance by april 27, 2020, the company may be eligible for an additional grace period. to qualify, the company would be required to meet the continued listing requirements for market value of publicly held shares and all other initial listing standards for the nasdaq capital market, with the exception of the minimum bid price requirement, and provide written notice of its intention to cure the minimum bid price deficiency during the second compliance period. if the company meets these requirements, the nasdaq staff will grant an additional 180 calendar days for the company to regain compliance with the minimum bid price requirement. if the nasdaq staff determines that the company will not be able to cure the deficiency, or if the company is otherwise not eligible for such additional compliance period, nasdaq will provide notice that the company’s common stock will be subject to delisting. the company would have the right to appeal a determination to delist its common stock, and the common stock would remain listed on the nasdaq capital market until the completion of the appeal process.
CTXR Ratings Summary
CTXR Quant Ranking